Clinical features of 309 patients with splenic MZL
. | No. patients (%) . | No. not available for assessment . |
|---|---|---|
| Men/women | 151/158 (49/51) | 0 |
| Ann Arbor stage | 0 | |
| I-II | 9 (3) | |
| III-IV | 300 (97) | |
| Splenomegaly | 290 (94) | 0 |
| Bone marrow involvement | 289 (94) | 0 |
| More than 1 extranodal site | 45 (15) | 0 |
| Nodal disease | 128 (41) | 0 |
| ECOG status 2 or greater | 30 (10) | 19 |
| B symptoms | 61 (20) | 0 |
| Liver involvement | 52 (17) | 0 |
| Leukemic disease | 177 (59) | 7 |
| Leukocyte count less than 3500/μL | 55 (18) | 5 |
| Lymphocyte count above 9000/μL | 77 (26) | 16 |
| Presence of villous lymphocytes | 55 (18) | 0 |
| Hemoglobin level less than 12 g/dL | 145 (48) | 6 |
| Platelet count less than 100 000/μL | 71 (24) | 7 |
| LDH level higher than normal | 76 (28) | 36 |
| β2-microglobulin level higher than normal | 121 (69) | 134 |
| Albumin level less than 3.5 g/dL | 34 (14) | 66 |
| Serum monoclonal component | 25 (8) | 0 |
| IgG | 4 | 0 |
| IgM | 19 | 0 |
| IgG/IgM | 1 | 0 |
| IgA | 1 | 0 |
| κ/λ | 20/5 | 0 |
| Autoimmune background | 28 (9) | 0 |
| Second cancer | 24 (8) | 0 |
| IPI score | 39 | |
| Low | 60 (22) | 0 |
| Low-intermediate | 144 (54) | 0 |
| High-intermediate | 60 (22) | 0 |
| High | 6 (2) | 0 |
. | No. patients (%) . | No. not available for assessment . |
|---|---|---|
| Men/women | 151/158 (49/51) | 0 |
| Ann Arbor stage | 0 | |
| I-II | 9 (3) | |
| III-IV | 300 (97) | |
| Splenomegaly | 290 (94) | 0 |
| Bone marrow involvement | 289 (94) | 0 |
| More than 1 extranodal site | 45 (15) | 0 |
| Nodal disease | 128 (41) | 0 |
| ECOG status 2 or greater | 30 (10) | 19 |
| B symptoms | 61 (20) | 0 |
| Liver involvement | 52 (17) | 0 |
| Leukemic disease | 177 (59) | 7 |
| Leukocyte count less than 3500/μL | 55 (18) | 5 |
| Lymphocyte count above 9000/μL | 77 (26) | 16 |
| Presence of villous lymphocytes | 55 (18) | 0 |
| Hemoglobin level less than 12 g/dL | 145 (48) | 6 |
| Platelet count less than 100 000/μL | 71 (24) | 7 |
| LDH level higher than normal | 76 (28) | 36 |
| β2-microglobulin level higher than normal | 121 (69) | 134 |
| Albumin level less than 3.5 g/dL | 34 (14) | 66 |
| Serum monoclonal component | 25 (8) | 0 |
| IgG | 4 | 0 |
| IgM | 19 | 0 |
| IgG/IgM | 1 | 0 |
| IgA | 1 | 0 |
| κ/λ | 20/5 | 0 |
| Autoimmune background | 28 (9) | 0 |
| Second cancer | 24 (8) | 0 |
| IPI score | 39 | |
| Low | 60 (22) | 0 |
| Low-intermediate | 144 (54) | 0 |
| High-intermediate | 60 (22) | 0 |
| High | 6 (2) | 0 |
Median age was 64 years (range, 33-86 years).